Researchers analyzed 10 randomized controlled trials and 30 observational studies with 5,668 patients.
Here’s what they found.
1. There was moderate-quality evidence for improvement in most metabolic parameters for subjects assigned to intragastric balloon therapy compared to conventional non-surgical therapy.
2. The odds ratio for diabetes resolution after intragastric balloons therapy was 1.4.
3. The balloons had a 1.3 percent rate of serious adverse events.
Researchers concluded, “IGBs are more effective than diet in improving obesity-related metabolic risk factors with a low rate of adverse effects, however the strength of the evidence is limited given the small number of participants and lack of long-term follow-up.”
More articles on gastroenterology/endoscopy:
GI leader to know: Dr. Anthony Grande of North Suburban Gastroenterology Associates
Allergan makes board changes: 3 things to know
Chemotherapy overused for young, middle-aged adults with colon cancer, no improvement in survival rate: 4 key notes
